{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:36:52Z","timestamp":1787323012480,"version":"build-2736575974"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Envision Ignite, an Envision Medical Communications agency"},{"name":"Envision Pharma Group"},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Effective, minimally invasive biomarkers are needed to predict treatment outcomes in ulcerative colitis (UC). This multicenter observational study investigated predictive serum and genetic biomarkers for vedolizumab (VDZ) therapy in UC, including serum leucine-rich \u03b1-2-glycoprotein (LRG), cytokines, and differentially expressed genes (DEGs) in intestinal tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients (18-80\u2009years; moderately to severely active UC) received intravenous VDZ (300\u2009mg; Weeks 0, 2, 6, then every 8 weeks through Week 54). Serum biomarkers were compared between those who did\/did not achieve clinical remission (CR; full Mayo score \u22642, all subscores \u22641) or mucosal healing (MH; Mayo endoscopic subscore \u22641) at Week 14. Week 0 inflammatory tissue data were stratified by Week 14 VDZ effect (CR and complete-MH [Mayo endoscopic subscore = 0]) for DEGs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 21 patients were included. Mean serum LRG was significantly lower in the CR (n\u2009=\u200911) versus non-CR (n\u2009=\u200910) group at Week 0 (19.0 vs 29.0\u2009\u00b5g\/mL; P\u00a0=\u00a0.0267) and Week 6 (13.4 vs 19.6\u2009\u00b5g\/mL; P\u00a0=\u00a0.0340), and in the MH (n\u2009=\u200914) versus non-MH (n\u2009=\u20097) group at Week 6 (13.7 vs 21.6\u2009\u00b5g\/mL; P\u00a0=\u00a0.0326). Mean monocyte chemoattractant protein-1 (MCP-1) was significantly different between CR and non-CR groups at Week 0 (609.0 vs 403.4\u2009pg\/mL; P\u00a0=\u00a0.0018) and MH versus non-MH at Week 0 (587.2 vs 358.9\u2009pg\/mL; P\u00a0&amp;lt;\u00a0.001) and Week 6 (606.9 vs 451.6\u2009pg\/mL; P\u00a0=\u00a0.037). No significant differences in C-reactive protein and fecal calprotectin levels were observed. DEGs included LRG1, LRG-related cytokines, and MCP1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum LRG and MCP-1 may be candidate biomarkers of VDZ treatment response in UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag084","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:22:52Z","timestamp":1786360972000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum leucine-rich \u03b1-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-9294","authenticated-orcid":false,"given":"Takeo","family":"Yoshihara","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine , Osaka 565-0871,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-618X","authenticated-orcid":false,"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hyogo Medical University School of Medicine , Hyogo 663-8501,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Naka","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University , Iwate 028-3694,","place":["Japan"]},{"name":"Division of Allergy and Rheumatology, Department of Internal Medicine, School of Medicine Iwate Medical University , Iwate 028-3695,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-3059","authenticated-orcid":false,"given":"Hideki","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine , Osaka 565-0871,","place":["Japan"]},{"name":"Osaka International Medical & Science Center, Osaka Keisatsu Hospital , Osaka 543-0042,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-3322","authenticated-orcid":false,"given":"Yoshito","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine , Osaka 565-0871,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OGF study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Uema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Otake-Kasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Japan Medical Office, Takeda Pharmaceutical Company Limited , Tokyo 103-8668,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Baba","sequence":"additional","affiliation":[{"name":"Japan Medical Office, Takeda Pharmaceutical Company Limited , Tokyo 103-8668,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine , Osaka 565-0871,","place":["Japan"]},{"name":"Department of Gastroenterology, Kansai Rosai Hospital , Hyogo 660-8511,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026082109370013200_otag084-B1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2026082109370013200_otag084-B2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.4049\/jimmunol.156.8.2851","article-title":"Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences","volume":"156","author":"Shyjan","year":"1996","journal-title":"J Immunol"},{"key":"2026082109370013200_otag084-B3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026082109370013200_otag084-B4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026082109370013200_otag084-B5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2014a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026082109370013200_otag084-B6","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3389\/fimmu.2018.01700","article-title":"Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases","volume":"9","author":"Rath","year":"2018","journal-title":"Front Immunol"},{"key":"2026082109370013200_otag084-B7","doi-asserted-by":"crossref","first-page":"29755","DOI":"10.1038\/s41598-024-80285-6","article-title":"Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease","volume":"14","author":"Amano","year":"2024","journal-title":"Sci Rep"},{"key":"2026082109370013200_otag084-B8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","article-title":"Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study","volume":"56","author":"Shinzaki","year":"2021","journal-title":"J Gastroenterol"},{"key":"2026082109370013200_otag084-B9","doi-asserted-by":"crossref","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","article-title":"Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease","volume":"11","author":"Yasutomi","year":"2021","journal-title":"Sci Rep"},{"key":"2026082109370013200_otag084-B10","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1038\/s41598-025-93831-7","article-title":"Leucine-rich alpha-2 glycoprotein could be clinically useful in active and postoperative Crohn\u2019s disease","volume":"15","author":"Tashiro","year":"2025","journal-title":"Sci Rep"},{"key":"2026082109370013200_otag084-B11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13497413.2018.1481582","article-title":"LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease","volume":"41","author":"Naka","year":"2018","journal-title":"Immunol Med"},{"key":"2026082109370013200_otag084-B12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/ibd.22936","article-title":"Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis","volume":"18","author":"Serada","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026082109370013200_otag084-B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis","volume":"11","author":"Shinzaki","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026082109370013200_otag084-B14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1084\/jem.169.4.1485","article-title":"Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line","volume":"169","author":"Matsushima","year":"1989","journal-title":"J Exp Med"},{"key":"2026082109370013200_otag084-B15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41598-021-04098-7","article-title":"CCR2 promotes monocyte recruitment and intestinal inflammation in mice lacking the interleukin-10 receptor","volume":"12","author":"El Sayed","year":"2022","journal-title":"Sci Rep"},{"key":"2026082109370013200_otag084-B16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gutjnl-2018-316772","article-title":"Non-classical monocyte homing to the gut via \u03b14\u03b27 integrin mediates macrophage-dependent intestinal wound healing","volume":"69","author":"Schleier","year":"2020","journal-title":"Gut"},{"key":"2026082109370013200_otag084-B17","doi-asserted-by":"crossref","first-page":"e0288147","DOI":"10.1371\/journal.pone.0288147","article-title":"Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease","volume":"18","author":"Ott","year":"2023","journal-title":"PLoS One"},{"key":"2026082109370013200_otag084-B18","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10620-019-05570-1","article-title":"Vedolizumab concentrations are associated with long-term endoscopic remission in patients with inflammatory bowel diseases","volume":"64","author":"Yarur","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2026082109370013200_otag084-B19","first-page":"407","article-title":"Predictors of the efficacy of vedolizumab in patients with ulcerative colitis","volume":"86","author":"Kajikawa","year":"2024","journal-title":"Nagoya J Med Sci"},{"key":"2026082109370013200_otag084-B20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ibd\/izy307","article-title":"Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis","volume":"25","author":"Battat","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026082109370013200_otag084-B21","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ecco-jcc\/jjz029","article-title":"Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis","volume":"13","author":"Pouillon","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026082109370013200_otag084-B22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026082109370013200_otag084-B23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12929-022-00790-6","article-title":"LRG1: an emerging player in disease pathogenesis","volume":"29","author":"Camilli","year":"2022","journal-title":"J Biomed Sci"},{"key":"2026082109370013200_otag084-B24","doi-asserted-by":"crossref","first-page":"e000208","DOI":"10.1136\/bmjgast-2018-000208","article-title":"Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD","volume":"5","author":"Soendergaard","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"key":"2026082109370013200_otag084-B25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026082109370013200_otag084-B26","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026082109370013200_otag084-B27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/jcm9030800","article-title":"On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases","volume":"9","author":"Caviglia","year":"2020","journal-title":"J Clin Med"},{"key":"2026082109370013200_otag084-B28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/jcm9051323","article-title":"Serum interleukin-6 and -8 as predictors of response to vedolizumab in inflammatory bowel diseases","volume":"9","author":"Bertani","year":"2020","journal-title":"J Clin Med"},{"key":"2026082109370013200_otag084-B29","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.3390\/ijms23073890","article-title":"The human monocyte-a circulating sensor of infection and a potent and rapid inducer of inflammation","volume":"23","author":"Lara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026082109370013200_otag084-B30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ibd\/izab117","article-title":"Response to anti-\u03b14\u03b27 blockade in patients with ulcerative colitis is associated with distinct mucosal gene expression profiles at baseline","volume":"28","author":"Gazouli","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026082109370013200_otag084-B31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000504323","article-title":"Siglec-14 enhances NLRP3-inflammasome activation in macrophages","volume":"12","author":"Tsai","year":"2020","journal-title":"J Innate Immun"},{"key":"2026082109370013200_otag084-B32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4049\/immunohorizons.1900093","article-title":"CD8+ T cells require ITK-mediated TCR signaling for migration to the intestine","volume":"4","author":"Cho","year":"2020","journal-title":"Immunohorizons"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag084\/70609413\/otag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag084\/70609413\/otag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:37:09Z","timestamp":1787319429000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag084\/8758885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag084","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag084"}}